Clinical trial · Observational
Using a Blood Test to Monitor Metastatic Breast Cancer Treatment
Using a Liquid Biopsy to Monitor Metastatic Breast Cancer Treatment
NCT05804578CI-TRIAL-00092628BEACONrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Change in ctDNA level from baseline to 6 months of treatment
- timeFrame
- Baseline - 6 months
- description
- The change in circulating tumour DNA methylation level over the course of treatment (Baseline blood draw, with timing of every standard of care blood draw for 8 weeks after treatment initiation, then monthly with standard of care blood draw for up to six after treatment initiation).
- measure
- Changes in radiographic tumour assessments for monitoring response to treatment
- timeFrame
- 3 months and 6 months
- description
- Radiographic tumor assessments will be performed as per RECIST v.1.1
- measure
- Change in measurable lytic lesions in participants with bone only metastasis assessed by CT scans as measured per RECIST v.1.1
- timeFrame
- 3 months and 6 months
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria -Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \[to be herein described as 'metastatic'\]
References
Publications (0)
Data not yet available
No reference posted for this study.